Impact News +++ Suzuki Motor Full-year Profit, Revenue Increase; Sees Lower Profit In Fiscal 2026 (AFX) +++ SUZUKI MOTOR Aktie +3,81%

BIOCRYST Aktie

>BIOCRYST Aktienkurs

8.294 EUR +1.1% (TradegateBSX)

Ask: 8.296 EUR / 663 Stück

Bid: 8.148 EUR / 676 Stück

Tagesumsatz: 7 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

BIOCRYST Aktie über LYNX handeln

Intraday

1 Jahr

>BIOCRYST Performance

1 Woche: +11,7%

1 Monat: +3,3%

3 Monate: +42,4%

6 Monate: +36,4%

1 Jahr: -9,7%

laufendes Jahr: +25,7%

>BIOCRYST Aktie

Name:

BIOCRYST PHARMACEUTICALS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US09058V1035 / 896047

Symbol/ Ticker:

BO1 (Frankfurt) / BCRX (NASDAQ)

Kürzel:

FRA:BO1, ETR:BO1, BO1:GR, NASDAQ:BCRX

Index:

Webseite:

https://www.biocryst.com/

Profil:

BioCryst Pharmaceuticals Inc. is a biotechnology company specializing in the research, development, and commercialization of novel small-molecule drugs that target key enzymes in infectious and inflammatory diseases. Leveraging expertise in biology, ..
>Volltext..

Marktkapitalisierung:

1857.43 Mio. EUR

Unternehmenswert:

2394.97 Mio. EUR

Umsatz:

754.41 Mio. EUR

EBITDA:

270.89 Mio. EUR

Nettogewinn:

-390.09 Mio. EUR

Gewinn je Aktie:

-1.47 EUR

Schulden:

730.87 Mio. EUR

Liquide Mittel:

146.88 Mio. EUR

Operativer Cashflow:

Bargeldquote:

1.22

Umsatzwachstum:

64.72%

Gewinnwachstum:

-702.02%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

BIOCRYST

Letzte Datenerhebung:

14.05.26

>BIOCRYST Kennzahlen

Aktien/ Unternehmen:

Aktien: 254.16 Mio. St.

Frei handelbar: 90.28%

Leerverk. Aktien: 14.72%

Rückkaufquote: -1.21%

Mitarbeiter: 435

Umsatz/Mitarb.: 1.71 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 175.03%

Bewertung:

KGV: -

KGV lG: -

KUV: 2.51

KBV: -

PEG-Ratio: -0.01

EV/EBITDA: 8.84

Rentabilität:

Bruttomarge: 97.52%

Gewinnmarge: -51.71%

Operative Marge: 35.67%

Managementeffizenz:

Gesamtkaprendite: -96.92%

Eigenkaprendite: -

>BIOCRYST Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>BIOCRYST Chart & Kurs - NASDAQ

>BIOCRYST News

13.05.26 - 13:03	BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 (GlobeNewswire EN)
	RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference taking place in Philadelphia from May 17–20, 2026....

13.05.26 - 10:03	Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition (PR Newswire)
	Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of the diagnosis and treatment of a rare, but not invisible, disease MILAN, May 13, 2026 /PRNewswire/......

12.05.26 - 19:36	BioCryst: Umsatz übertrifft Erwartungen, doch Gewinn pro Aktie enttäuscht massiv (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 21:24	BioCryst (BCRX) Q1 2026 Earnings Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 18:15	BioCryst maintains $625M-$645M 2026 ORLADEYO revenue outlook while signing $70M upfront navenibart Europe license (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.05.26 - 16:45	BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates (Zacks)
	BioCryst (BCRX) delivered earnings and revenue surprises of -150.00% and +0.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?...

06.05.26 - 15:33	Full Transcript: BioCryst Pharma Q1 2026 Earnings Call (Benzinga)
	Importance Rank: 1 read more...

06.05.26 - 13:03	BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire EN)
	— Q1 2026 ORLADEYO® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —...

05.05.26 - 13:03

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 61,750 shares of BioCryst common stock. The RSUs were granted as of May 1, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....

04.05.26 - 13:03	BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema (GlobeNewswire EN)
	— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —...

28.04.26 - 13:03	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire EN)
	RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:...

15.04.26 - 13:03	BioCryst to Report First Quarter 2026 Financial Results on May 6 (GlobeNewswire EN)
	RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results on Wednesday, May 6, 2026....

06.04.26 - 13:03	BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer (GlobeNewswire EN)
	— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — ...

03.04.26 - 13:03

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

RESEARCH TRIANGLE PARK, N.C., April 03, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 12 newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 123,350 shares, of BioCryst common stock. The options and RSUs were granted as of April 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....

28.03.26 - 03:54	BioCryst Q4 2025: Starkes Wachstum, doch Aktie gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

25.03.26 - 00:01	Insiderhandel: Aufsichtsrat verkauft Aktien von BioCryst Pharmaceuticals im Wert von 504823 USD (Insiderkauf)
	Heggie, Theresa - Aufsichtsrat - Tag der Transaktion: 2026-03-20...

19.03.26 - 12:01	Insiderhandel: Chief Legal Officer verkauft Aktien von BioCryst Pharmaceuticals im Wert von 1372500 USD (Insiderkauf)
	Barnes, Alane P. - Vorstand - Tag der Transaktion: 2026-03-16...

16.03.26 - 16:19	BioCryst gains amid takeover speculation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.03.26 - 13:03

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)

RESEARCH TRIANGLE PARK, N.C., March 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the compensation committee of BioCryst's board of directors granted six newly-hired employees restricted stock units (RSUs) covering an aggregate of 65,850 shares of BioCryst common stock. The RSUs were granted as of March 2, 2026, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....

03.03.26 - 17:12	BioCryst skizziert Wachstumspläne und peilt Milliardenumsatz an (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn zwei Wesen, die miteinander durchs Leben gehen wollen, nichts als ihr Liebesgefühl haben, so sind ihre Quellen schnell erschöpft, und bald stellen sich Gleichgültigkeit, Übersättigung, Widerwille ein. - Honoré de Balzac

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram